[go: up one dir, main page]

WO2004042077A3 - Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b) - Google Patents

Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b) Download PDF

Info

Publication number
WO2004042077A3
WO2004042077A3 PCT/EP2003/011883 EP0311883W WO2004042077A3 WO 2004042077 A3 WO2004042077 A3 WO 2004042077A3 EP 0311883 W EP0311883 W EP 0311883W WO 2004042077 A3 WO2004042077 A3 WO 2004042077A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorders
pde8b
therapeutics
diagnostics
diseases associated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2003/011883
Other languages
English (en)
Other versions
WO2004042077A2 (fr
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to AU2003279323A priority Critical patent/AU2003279323A1/en
Priority to EP03772262A priority patent/EP1601782A2/fr
Publication of WO2004042077A2 publication Critical patent/WO2004042077A2/fr
Publication of WO2004042077A3 publication Critical patent/WO2004042077A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04053—3',5'-Cyclic-AMP phosphodiesterase (3.1.4.53)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une PDE8B humaine qui est associée aux troubles du système nerveux périphérique et central, aux maladies cardiovasculaires, aux maladies endocrinologiques, aux troubles urologiques, aux troubles de la reproduction et aux maladies métaboliques. Cette invention concerne également des méthodes de criblage permettant d'identifier des composés servant au traitement ou à la prévention de troubles du système nerveux périphérique et central, de maladies cardiovasculaires, de maladies endocrinologiques, de troubles urologiques et de maladies métaboliques. Cette invention concerne en outre des composés qui se lient à la PDE8B et/ou qui activent ou inhibent l'activité de la PDE8B ainsi que des compositions pharmaceutiques renfermant ces composés.
PCT/EP2003/011883 2002-11-08 2003-10-25 Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b) Ceased WO2004042077A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2003279323A AU2003279323A1 (en) 2002-11-08 2003-10-25 Diagnostics and therapeutics for diseases associated with human phosphodiesterase 8b (pde8b)
EP03772262A EP1601782A2 (fr) 2002-11-08 2003-10-25 Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02024999 2002-11-08
EP02024999.1 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004042077A2 WO2004042077A2 (fr) 2004-05-21
WO2004042077A3 true WO2004042077A3 (fr) 2005-01-13

Family

ID=32309323

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011883 Ceased WO2004042077A2 (fr) 2002-11-08 2003-10-25 Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b)

Country Status (3)

Country Link
EP (1) EP1601782A2 (fr)
AU (1) AU2003279323A1 (fr)
WO (1) WO2004042077A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5435529B2 (ja) 2005-09-02 2014-03-05 東レ株式会社 腎ガン診断、腎ガン患者予後予測のための組成物および方法
WO2009091023A1 (fr) 2008-01-17 2009-07-23 Toray Industries, Inc. Composition et procédé de diagnostic ou de détection du cancer de l'estomac

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932423A (en) * 1996-03-25 1999-08-03 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
US6080548A (en) * 1997-11-19 2000-06-27 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
WO2000077040A2 (fr) * 1999-06-16 2000-12-21 Incyte Genomics, Inc. Molecules de signalisation intracellulaires
WO2001098471A2 (fr) * 2000-06-22 2001-12-27 Incyte Genomics, Inc. Phosphodiesterases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5932423A (en) * 1996-03-25 1999-08-03 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
US6080548A (en) * 1997-11-19 2000-06-27 Incyte Pharmaceuticals, Inc. Cyclic nucleotide phosphodiesterases
WO2000077040A2 (fr) * 1999-06-16 2000-12-21 Incyte Genomics, Inc. Molecules de signalisation intracellulaires
WO2001098471A2 (fr) * 2000-06-22 2001-12-27 Incyte Genomics, Inc. Phosphodiesterases

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL [online] EBI; 21 December 2000 (2000-12-21), XP002283156, retrieved from EBI Database accession no. AAB64411 *
DATABASE EMBL [online] EBI; 27 December 2001 (2001-12-27), XP002283155, retrieved from EBI Database accession no. ABB09006 *
DATABASE EMBL [online] EBI; 27 February 2000 (2000-02-27), XP002283154, retrieved from EBI Database accession no. AAB11938 *
HAYASHI M ET AL: "Molecular cloning and characterization of human PDE8B, a novel thyroid-specific isozyme of 3',5'-cyclic nucleotide phosphodiesterase", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 250, no. 3, 29 September 1998 (1998-09-29), pages 751 - 756, XP002091362, ISSN: 0006-291X *
HAYASHI MASAAKI ET AL: "Genomic organization, chromosomal localization, and alternative splicing of the human phosphodiesterase 8B gene", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 297, no. 5, 11 October 2002 (2002-10-11), pages 1253 - 1258, XP002255295, ISSN: 0006-291X *
PEREZ-TORRES S ET AL: "Alterations on phosphodiesterase type 7 and 8 isozyme mRNA expression in Alzheimer's disease brains examined by in situ hybridization.", EXPERIMENTAL NEUROLOGY, vol. 182, no. 2, August 2003 (2003-08-01), pages 322 - 334, XP002283149, ISSN: 0014-4886 *
See also references of EP1601782A2 *

Also Published As

Publication number Publication date
WO2004042077A2 (fr) 2004-05-21
AU2003279323A1 (en) 2004-06-07
EP1601782A2 (fr) 2005-12-07

Similar Documents

Publication Publication Date Title
WO2004104216A3 (fr) Diagnostics et agents therapeutiques destines a des maladies liees a une dipeptidylpeptidase iv (dpp4)
WO2004042389A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2003093816A3 (fr) Diagnostics et therapeutiques pour lutter contre des maladies associees au recepteur de l'oxytocine (oxtr)
WO2005022164A3 (fr) Agents diagnostiques et agents therapeutiques destines a des maladies associees a la kallikreine 8 (klk8)
WO2004042402A3 (fr) Moyens diagnostiques et therapeutiques destines a des maladies associees au mrgx1 humain
WO2004042077A3 (fr) Diagnostics et traitements de maladies associees a la phosphodiesterase 8b humaine (pde8b)
WO2004038405A3 (fr) Diagnostics et therapeutiques pour maladies liees au recepteur 43 couple a la proteine g (gpr43)
WO2004071378A3 (fr) Methodes diagnostiques et therapeutiques relatives a des etats pathologiques lies au recepteur hm74a couple a la proteine g
WO2004081563A3 (fr) Moyens de diagnostic et therapeutiques pour des maladies associees a la phosphodiesterase 1a (pde1a)
WO2004042390A3 (fr) Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4b (pde4b) humaine
WO2004029617A3 (fr) Diagnostic et therapeutique de maladies associees a la phosphodiesterase humaine 11a (pde11a)
WO2003096020A3 (fr) Diagnostic et traitement de maladies liees au recepteur 8 des chimiokines (ccr8)
WO2004038421A3 (fr) Agents diagnostiques et therapeutiques pour maladies associees au recepteur 41 couple a une proteine g humaine (gpr41)
WO2004038407A3 (fr) Diagnostics et medicaments pour maladies associees au recepteur 12 humain couple a la proteine g (gpr12)
WO2004073587A3 (fr) Diagnostics et traitements de maladies associees au recepteur de la parathormone 1 (pthr1)
WO2003066077A3 (fr) Outil de diagnostic et therapeutique pour des maladies associees au recepteur de neuromedine u1 (nmu1)
WO2004071393A3 (fr) Diagnostic et therapeutique pour des maladies associees au recepteur peptide 1 de type glucagon
WO2005040401A3 (fr) Diagnostic et traitement de maladies associees a la serine-protease mosaique (msp)
WO2004042076A3 (fr) Diagnostic et therapeutique de maladies associees a la phosphodiesterase 4a (pde4a) humaine
WO2003100434A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 2 de l'arginine vasopressine (avpr2)
WO2004042405A3 (fr) Diagnostic et therapeutique pour maladies associees au recepteur 3 couples aux proteines g (gpr3) humain
WO2003100433A3 (fr) Diagnostics et therapies pour maladies liees au recepteur 3 de l'arginine vasopressine (avpr3)
WO2004038416A8 (fr) Diagnostic et therapeutique de maladies associees au recepteur 6 couple a la proteine g humain (gpr6)
WO2004071394A3 (fr) Agents de diagnostic et de traitement destines aux maladies associees a hm74 (hm74)
WO2004050903A3 (fr) Methodes diagnostiques et therapeutiques concernant des maladies associees a la phosphodiesterase 4c (pde4c) humaine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003772262

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003772262

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP